Literature DB >> 23438799

Volume replacement therapy during hip arthroplasty using hydroxyethyl starch (130/0.4) compared to lactated Ringer decreases allogeneic blood transfusion and postoperative infection.

Adilson Hamaji1, Ludhmila Hajjar, Marcelo Caiero, Juliano Almeida, Rosana Ely Nakamura, Eduardo A Osawa, Julia Fukushima, Filomena R Galas, Jose Otavio Costa Auler Junior.   

Abstract

BACKGROUND AND OBJECTIVES: Hydroxyethyl starch (HES) 130/0.4 is considered an effective plasma expander when compared to crystalloids. There is controversy around its superiority regarding hemodynamic optimization and about possible detrimental effects on coagulation. The aim of this study was to compare the effects of HES 130/0.4 to lactated Ringer solution during hip arthroplasty in adult patients under spinal anesthesia regarding intraoperative bleeding, hemodynamic parameters, coagulation profile, transfusion requirements and clinical outcomes.
METHODS: In this randomized, controlled trial, 48 patients scheduled for hip arthroplasty with spinal anesthesia were randomized into two groups: 24 patients were allocated to receive a preload of 15 mL.kg(-1) of HES 130/0.4 and 24 patients received a preload of 30 mL.kg(-1) lactated Ringer solution before surgery. Hemodynamic measurements, hemoglobin concentrations, biochemical parameters and coagulation tests were evaluated in three periods during surgical procedure. Patients received medical follow-up during their hospital stay and up to postoperative 30 days. Primary outcome was the requirement of red blood cell transfusion between groups during hospital stay. Secondary outcome were hemodynamic parameters, length of hospital stay, mortality and occurrence of clinical postoperative complications.
RESULTS: Red blood cell transfusion was required in 17% of patients in the HES group and in 46% in the Ringer group (p = .029). Postoperative infections were more frequently observed in the Ringer group (17%) compared to the HES group (0), p = .037. There were no significant differences between groups in mortality, hospital length of stay and clinical complications other than infection.
CONCLUSIONS: During hip arthroplasty, patients treated with hypervolemic hemodilution with hydroxyethyl starch 130/0.4 required less transfusion and presented lower infection rate compared to patients who received lactated Ringer.
Copyright © 2013 Elsevier Editora Ltda. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23438799     DOI: 10.1016/S0034-7094(13)70196-X

Source DB:  PubMed          Journal:  Braz J Anesthesiol


  5 in total

1.  The effect of 0.5 L 6% hydroxyethyl starch 130/0.42 versus 1 L Ringer's lactate preload on the hemodynamic status of parturients undergoing spinal anesthesia for elective cesarean delivery using arterial pulse contour analysis.

Authors:  Paraskevi Matsota; Agathi Karakosta; Ageliki Pandazi; Dimitra Niokou; Kalliopi Christodoulaki; Georgia Kostopanagiotou
Journal:  J Anesth       Date:  2014-09-30       Impact factor: 2.078

Review 2.  Safety evaluation on low-molecular-weight hydroxyethyl starch for volume expansion therapy in pediatric patients: a meta-analysis of randomized controlled trials.

Authors:  Lixia Li; Yongyang Li; Xiaoxing Xu; Bo Xu; Rongrong Ren; Yan Liu; Jian Zhang; Bin He
Journal:  Crit Care       Date:  2015-03-10       Impact factor: 9.097

Review 3.  Hydroxyeyhyl starch: Controversies revisited.

Authors:  Rashmi Datta; Rajeev Nair; Anil Pandey; Nitish Gupta; Tapan Sahoo
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2014-10

4.  Clinical strategies to accelerate recovery after surgery orthopedic femur in elderly patients.

Authors:  Luiz Eduardo Imbelloni; Danielly Gomes; Rafaela Lopes Braga; Geraldo Borges de Morais Filho; Alberto da Silva
Journal:  Anesth Essays Res       Date:  2014 May-Aug

5.  Administration of HES in elderly patients undergoing hip arthroplasty under spinal anesthesia is not associated with an increase in renal injury.

Authors:  Yuanyuan Zhang; Yonghao Yu; Junya Jia; Wenli Yu; Rubin Xu; Licheng Geng; Ying Wei
Journal:  BMC Anesthesiol       Date:  2017-02-21       Impact factor: 2.217

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.